The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study (Q27853110)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study |
scientific article |
Statements
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. (English)
Richard S Finn
John P Crown
Istvan Lang
Katalin Boer
Sergey O Kulyk
Johannes Ettl
Ravindranath Patel
Tamas Pinter
Marcus Schmidt
Yaroslav Shparyk
Anu R Thummala
Nataliya L Voytko
Camilla Fowst
Xin Huang
Sindy T Kim
Sophia Randolph
Dennis J Slamon
January 2015
0 references
Identifiers
2 references
2 references